Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Celecoxib in Advanced "Cold" Solid Tumors
NCT03864575Phase 2Unknown
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, celecoxib in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), bladder cancer. Status: unknown.
02
Drugs
nivolumabcelecoxib
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)head and neck squamous cell carcinoma (HNSCC)bladder cancer
Beyond the preview
Go deeper on NCT03864575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864575.